Patents by Inventor Joseph R. Stringer
Joseph R. Stringer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11814445Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 14, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Kelli Jette, Yili Sun
-
Patent number: 11814444Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 14, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
-
Publication number: 20230303625Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: September 27, 2022Publication date: September 28, 2023Applicant: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole HA, Hyewon Youm, Mark W. EMBREY, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. GILBERT, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20230115176Abstract: The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.Type: ApplicationFiled: March 27, 2020Publication date: April 13, 2023Inventors: Willmen Wing-Menn Youngsaye, Bolin Geng, Michael R. Hale, Vincent P. Galullo, Jayashree G. Tikhe, Timothy Ryan Siegert, Alonso Ricardo, Derek M. LaPlaca, Douangsone D. Vadysirisack, Guo-Qing Tang, Kathleen Seyb, Michelle Denise Hoarty, Jonathan C. Blain, Joseph R. Stringer, Yongjin Gong, Claudio Sturino, Shawn Gallagher-Duval, Colin Diner, Burcin Akgun, Qing Cao, Douglas A. Treco, Vaishnavi Rajagopal, Ketki Ashok Dhamnaskar, Zhong Ma, Susan Ashwell, Jennifer Davoren, Xiaorong Liu, Camil Sayegh, Wenqing Xu, Alex Lemire, Audrey Belouin, Alexandria Jeanneret, Andrew Hildering, Barbara Bertani, Fabrizio MIcheli, Bemardo Pezzati, Alfonso Pozzan
-
Patent number: 11530244Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: December 20, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20220348610Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: June 20, 2019Publication date: November 3, 2022Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
-
Publication number: 20220089640Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: June 20, 2019Publication date: March 24, 2022Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Kelli Jette, Yili Sun
-
Publication number: 20210284694Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: June 20, 2019Publication date: September 16, 2021Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Patent number: 8618327Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alkyl groups, and optionally having hydroxyl and/or alkoxyl groups substituents.Type: GrantFiled: July 6, 2012Date of Patent: December 31, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Helen E. Blackwell, Matthew D. Bowman, Jennifer C. O'Neill, Joseph R. Stringer
-
Patent number: 8367680Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use.Type: GrantFiled: March 27, 2009Date of Patent: February 5, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Helen E. Blackwell, Matthew D. Bowman, Joseph R. Stringer
-
Publication number: 20120277252Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alkyl groups, and optionally having hydroxyl and/or alkoxyl groups substituents.Type: ApplicationFiled: July 6, 2012Publication date: November 1, 2012Inventors: Helen E. Blackwell, Matthew D. Bowman, Jennifer C. O'Neill, Joseph R. Stringer
-
Patent number: 8227616Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alky groups, and optionally having hydroxyl and/or alkoxyl groups substituents.Type: GrantFiled: June 14, 2010Date of Patent: July 24, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Helen E. Blackwell, Matthew D. Bowman, Jennifer C. O'Neill, Joseph R. Stringer
-
Publication number: 20100261763Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alky groups, and optionally having hydroxyl and/or alkoxyl groups substituents.Type: ApplicationFiled: June 14, 2010Publication date: October 14, 2010Inventors: Helen E. BLACKWELL, Matthew D. BOWMAN, Jennifer C. O'NEILL, Joseph R. STRINGER
-
Patent number: 7737164Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alky groups, and optionally having hydroxyl and/or alkoxyl groups substituents.Type: GrantFiled: May 16, 2007Date of Patent: June 15, 2010Assignee: Wisconsin Alumni Research FoundationInventors: Helen E. Blackwell, Matthew D. Bowman, Jennifer C. O'Neill, Joseph R. Stringer
-
Publication number: 20090270423Abstract: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use.Type: ApplicationFiled: March 27, 2009Publication date: October 29, 2009Inventors: Helen E. Blackwell, Matthew D. Bowman, Joseph R. Stringer